Statement: sufferers of hyperthyroidism are excluded from the primary trial.
Primary_evidence: Inclusion Criteria:   Subjects will only be included in the study if they meet all of the following criteria:   Subjects who have given informed consent   Subjects that agree not to drink alcoholic beverages or use any drugs during the study   Subject with blood parameters within normal ranges   Age: at least 18 years old   Patients will only be included in the study if they meet all of the following criteria:   Patients who have given informed consent   Patients that agree not to drink alcoholic beverages or use any drugs during the study   Age: at least 18 years old   Patients with local, locally advanced or metastatic HER2+ breast carcinoma as diagnosed on biopsied tissue by immunohistochemistry or fluorescence in situ hybridization (FISH). Exclusion Criteria:   Patients will not be included in the study if one of the following criteria applies:   Pregnant patients   Breast feeding patients   Patients with occupational exposure to ionizing irradiation   Patients with previous thyroid disorders   Patients that received radiolabeled compounds with a long half-life (>7h) for diagnostic or therapeutic purposes within the last 2 days.   Patients with absolute contra-indications for thyroid blockage with potassium iodide.   Patients with abnormal liver: ALT/AST > 2 times normal values; bilirubin > 1.5 time normal values.   Patients with abnormal kidney function: < 50 ml/min/1,73 m2   Patients with recent (< 1 week) gastrointestinal disorders (CTCAE v4.0 grade 3 or 4) with diarrhea as major symptom   Patients with any serious active infection   Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical   Patients who cannot communicate reliably with the investigator   Patients who are unlikely to cooperate with the requirements of the study   Patients at increased risk of death from a pre-existing concurrent illness   Patients who participated already in this study   Patients who participated in a previous trial with Anti-HER2 VHH1   Subjects will not be included in the study if one of the following criteria applies:   Pregnant subjects   Breast feeding subjects   Subjects with occupational exposure to ionizing irradiation   Subjects with clinical significant disease or on concomitant therapy (except contraception)   Subjects with previous thyroid disorders   Subjects that received radiolabeled compounds with a long half-life (>7h) for diagnostic or therapeutic purposes within the last 2 days.   Subjects with absolute contra-indications for thyroid blockage with potassium iodide.   Subjects with abnormal liver: ALT/AST > 2 times normal values; bilirubin > 1.5 time normal values.   Subjects with abnormal kidney function: < 50 ml/min/1,73 m2   Subjects with recent (< 1 week) gastrointestinal disorders (CTCAE v4.0 grade 3 or 4) with diarrhea as major symptom   Subjects with any serious active infection   Subjects who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test radiopharmaceutical   Subjects who cannot communicate reliably with the investigator   Subjects who are unlikely to cooperate with the requirements of the study   Subjects at increased risk of death from a pre-existing concurrent illness   Subjects who participated already in this study   Subjects who participated in a previous trial with Anti-HER2 VHH1